anti-CD44v9-MMAF / CrossBridge Bio - LARVOL DELTA

CD44v9-targeted antibody-drug conjugate as a novel therapy for advanced breast cancer (AACR 2026) - "Background: Aggressive breast cancers, including triple-negative and inflammatory subtypes, urgently require novel therapeutic strategies. CD44v9 is a tumor-specific, biologically meaningful target for ADC development in advanced breast cancer. The preclinical efficacy and selectivity of anti-CD44v9-MMAF highlight its potential as a next-generation therapy for patients with CD44v9-positive, treatment-refractory breast cancers."

ADC • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2